staurosporine has been researched along with Abnormalities, Autosome in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (60.00) | 29.6817 |
2010's | 1 (20.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
Authors | Studies |
---|---|
George, TI; Gotlib, J; Reiter, A | 1 |
Bhatnagar, B; Blum, W; Canning, R; Devine, SM; Garzon, R; Geyer, S; Klisovic, R; Marcucci, G; Vasu, S; Walker, AR; Walsh, K; Wang, H; Wu, YZ | 1 |
Cavelier, C; Demur, C; Didier, C; Ducommun, B; Manenti, S; Mansat-De Mas, V; Prade, N; Recher, C | 1 |
Azuma, A; Chubb, S; Guo, Y; Hittelman, W; Huang, P; Jiang, Y; Li, Y; Liu, X; Matsuda, A; Plunkett, W | 1 |
Guo, L; Liu, X; Nishikawa, K; Plunkett, W | 1 |
1 review(s) available for staurosporine and Abnormalities, Autosome
Article | Year |
---|---|
New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis.
Topics: Animals; Chromosome Aberrations; Hematopoietic Stem Cell Transplantation; Humans; Mastocytosis, Systemic; Mutation; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrazoles; Pyrroles; Staurosporine; Triazines | 2020 |
4 other study(ies) available for staurosporine and Abnormalities, Autosome
Article | Year |
---|---|
Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chromosome Aberrations; Cytarabine; Drug Monitoring; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Retreatment; Staurosporine; Treatment Outcome; Young Adult | 2016 |
Constitutive activation of the DNA damage signaling pathway in acute myeloid leukemia with complex karyotype: potential importance for checkpoint targeting therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Checkpoint Kinase 1; Child; Chromosome Aberrations; DNA Damage; Flow Cytometry; Fluorescent Antibody Technique; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Middle Aged; Protein Kinases; RNA Interference; Signal Transduction; Staurosporine | 2009 |
Molecular basis for G2 arrest induced by 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine and consequences of checkpoint abrogation.
Topics: Antineoplastic Agents; Apoptosis; CDC2 Protein Kinase; Cell Line, Tumor; Checkpoint Kinase 1; Chromosome Aberrations; Cytarabine; DNA Damage; Drug Interactions; G2 Phase; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Mitosis; Protein Kinases; Signal Transduction; Staurosporine | 2005 |
Inhibition of topoisomerase IIalpha and G2 cell cycle arrest by NK314, a novel benzo[c]phenanthridine currently in clinical trials.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Cell Line, Tumor; Chromosome Aberrations; Clinical Trials as Topic; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Enzyme Inhibitors; G2 Phase; Histones; Humans; Leukemia, Myeloid, Acute; Phenanthrenes; Phenanthridines; Phosphorylation; Staurosporine; Topoisomerase II Inhibitors | 2007 |